Paucity of β2-microglobulin expression on small cell lung cancer, bronchial carcinoids, and certain other neuroendocrine tumors

K. Funa, A. F. Gazdar, J. D. Minna, R. I. Linnoila

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Cell lines established from small cell lung cancer (SCLC), a neuroendocrine tumor, have low or absent expression of class I major histocompatibility complex antigens. To determine whether this phenomenon occurs also in vivo, 244 routine paraffin-embedded tumors including 32 SCLC and 79 non-SCLC (NSCLC) lung cancers were studied for expression of β2-microglobulin (β2m) by an avidin-biotin coupled immunoperoxidase technique. The majority of SCLC tumors lacked β2m expression, while some had weak, focal expression. In contrast, most NSCLC expressed β2m, often strongly. The difference between SCLC and NSCLC was highly significant statistically, suggesting that β2m can be used as a clinical immunodiagnostic marker for distinguishing NSCLC from SCLC. In addition, certain other neuroendocrine tumors (neuroblastoma, bronchial and midgut carcinoid tumors) lacked β2m expression, whereas some (pheochromocytoma, medullary thyroid carcinoma, and peripheral neuroectodermal tumors) usually stained positively. Such non-neuroendocrine tumors as colon, breast, and prostate carcinomas showed moderate to high expression of β2m. Selective absence of β2m expression by certain neuroendocrine tumors appears to be a phenomenon of biological and diagnostic importance.

Original languageEnglish (US)
Pages (from-to)186-193
Number of pages8
JournalLaboratory Investigation
Volume55
Issue number2
StatePublished - 1986

Fingerprint

Neuroendocrine Tumors
Small Cell Lung Carcinoma
Carcinoid Tumor
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Peripheral Primitive Neuroectodermal Tumors
Biological Phenomena
Neoplasms
Histocompatibility Antigens Class I
Avidin
Pheochromocytoma
Biotin
Major Histocompatibility Complex
Neuroblastoma
Immunoenzyme Techniques
Paraffin
Prostate
Colon
Biomarkers
Breast Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Paucity of β2-microglobulin expression on small cell lung cancer, bronchial carcinoids, and certain other neuroendocrine tumors. / Funa, K.; Gazdar, A. F.; Minna, J. D.; Linnoila, R. I.

In: Laboratory Investigation, Vol. 55, No. 2, 1986, p. 186-193.

Research output: Contribution to journalArticle

@article{50fd83a2569b430fb6834899fc42ca09,
title = "Paucity of β2-microglobulin expression on small cell lung cancer, bronchial carcinoids, and certain other neuroendocrine tumors",
abstract = "Cell lines established from small cell lung cancer (SCLC), a neuroendocrine tumor, have low or absent expression of class I major histocompatibility complex antigens. To determine whether this phenomenon occurs also in vivo, 244 routine paraffin-embedded tumors including 32 SCLC and 79 non-SCLC (NSCLC) lung cancers were studied for expression of β2-microglobulin (β2m) by an avidin-biotin coupled immunoperoxidase technique. The majority of SCLC tumors lacked β2m expression, while some had weak, focal expression. In contrast, most NSCLC expressed β2m, often strongly. The difference between SCLC and NSCLC was highly significant statistically, suggesting that β2m can be used as a clinical immunodiagnostic marker for distinguishing NSCLC from SCLC. In addition, certain other neuroendocrine tumors (neuroblastoma, bronchial and midgut carcinoid tumors) lacked β2m expression, whereas some (pheochromocytoma, medullary thyroid carcinoma, and peripheral neuroectodermal tumors) usually stained positively. Such non-neuroendocrine tumors as colon, breast, and prostate carcinomas showed moderate to high expression of β2m. Selective absence of β2m expression by certain neuroendocrine tumors appears to be a phenomenon of biological and diagnostic importance.",
author = "K. Funa and Gazdar, {A. F.} and Minna, {J. D.} and Linnoila, {R. I.}",
year = "1986",
language = "English (US)",
volume = "55",
pages = "186--193",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Paucity of β2-microglobulin expression on small cell lung cancer, bronchial carcinoids, and certain other neuroendocrine tumors

AU - Funa, K.

AU - Gazdar, A. F.

AU - Minna, J. D.

AU - Linnoila, R. I.

PY - 1986

Y1 - 1986

N2 - Cell lines established from small cell lung cancer (SCLC), a neuroendocrine tumor, have low or absent expression of class I major histocompatibility complex antigens. To determine whether this phenomenon occurs also in vivo, 244 routine paraffin-embedded tumors including 32 SCLC and 79 non-SCLC (NSCLC) lung cancers were studied for expression of β2-microglobulin (β2m) by an avidin-biotin coupled immunoperoxidase technique. The majority of SCLC tumors lacked β2m expression, while some had weak, focal expression. In contrast, most NSCLC expressed β2m, often strongly. The difference between SCLC and NSCLC was highly significant statistically, suggesting that β2m can be used as a clinical immunodiagnostic marker for distinguishing NSCLC from SCLC. In addition, certain other neuroendocrine tumors (neuroblastoma, bronchial and midgut carcinoid tumors) lacked β2m expression, whereas some (pheochromocytoma, medullary thyroid carcinoma, and peripheral neuroectodermal tumors) usually stained positively. Such non-neuroendocrine tumors as colon, breast, and prostate carcinomas showed moderate to high expression of β2m. Selective absence of β2m expression by certain neuroendocrine tumors appears to be a phenomenon of biological and diagnostic importance.

AB - Cell lines established from small cell lung cancer (SCLC), a neuroendocrine tumor, have low or absent expression of class I major histocompatibility complex antigens. To determine whether this phenomenon occurs also in vivo, 244 routine paraffin-embedded tumors including 32 SCLC and 79 non-SCLC (NSCLC) lung cancers were studied for expression of β2-microglobulin (β2m) by an avidin-biotin coupled immunoperoxidase technique. The majority of SCLC tumors lacked β2m expression, while some had weak, focal expression. In contrast, most NSCLC expressed β2m, often strongly. The difference between SCLC and NSCLC was highly significant statistically, suggesting that β2m can be used as a clinical immunodiagnostic marker for distinguishing NSCLC from SCLC. In addition, certain other neuroendocrine tumors (neuroblastoma, bronchial and midgut carcinoid tumors) lacked β2m expression, whereas some (pheochromocytoma, medullary thyroid carcinoma, and peripheral neuroectodermal tumors) usually stained positively. Such non-neuroendocrine tumors as colon, breast, and prostate carcinomas showed moderate to high expression of β2m. Selective absence of β2m expression by certain neuroendocrine tumors appears to be a phenomenon of biological and diagnostic importance.

UR - http://www.scopus.com/inward/record.url?scp=0022531993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022531993&partnerID=8YFLogxK

M3 - Article

C2 - 3525983

AN - SCOPUS:0022531993

VL - 55

SP - 186

EP - 193

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 2

ER -